share_log

The FDA Has Granted RMAT Designation To The Combination Therapy Of Affimed's Acimtamig And Artiva Biotherapeutic's AlloNK (AB101) For Relapsed Or Refractory Hodgkin Lymphoma

Benzinga ·  Dec 5 19:34

The combination is being evaluated in the on-going LuminICE-203 multicenter, multi-cohort phase 2 trial.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment